AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology

December 19, 2019 GMT

IRVINE, Calif.--(BUSINESS WIRE)--Dec 19, 2019--

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the United States Patent and Trademark Office has issued or allowed Axonics nine U.S. utility patents in 2019, along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

The U.S. patents range in subject matter and include coverage of the Axonics lead design, patient remote control, external trial system, wireless charging, current control stimulation, electromyography and internal system electronics. The U.S. patents are: 10,478,619; 10,406,369; 10,384,067; 10,376,704; 10,447,083; 10,449,277 and 15/719,461; 15/416,888; 15/980,642.

“The volume, subject matter diversity, and breadth of important geographies demonstrate the investment in innovation that Axonics continues to make in the miniaturized and rechargeable sacral neuromodulation technology space,” said Raymond W. Cohen, Chief Executive Officer.

The Axonics patent portfolio represents technology internally developed by Axonics and technology developed under license from the Alfred Mann Foundation.

The Axonics r-SNM ® System has obtained U.S. Food & Drug Administration (FDA) approval, European CE Mark approval, Health Canada approval, and Australian Therapeutic Goods Administration approval for the treatment of overactive bladder, urinary retention and fecal incontinence.

Currently, Axonics is in the initial phase of its launch in the United States following FDA approvals in September and November 2019. The Company has been marketing in select countries in Europe and Canada since the second half of 2018.

About Axonics Modulation Technologies, Inc. and Sacral Neuromodulation

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company’s website at www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191219005171/en/

CONTACT: Axonics’ Contact

Axonics Modulation Technologies, Inc.

Dan Dearen, +1-949-396-6320

President & Chief Financial Officer

ir@axonics.com

Investor & Media Contact

W2Opure

Matt Clawson, +1-949-370-8500

mclawson@w2ogroup.com

KEYWORD: AUSTRALIA NORTH AMERICA ASIA PACIFIC JAPAN CANADA EUROPE UNITED STATES AUSTRALIA/OCEANIA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH MEDICAL DEVICES

SOURCE: Axonics Modulation Technologies, Inc.

Copyright Business Wire 2019.

PUB: 12/19/2019 06:00 AM/DISC: 12/19/2019 06:01 AM

http://www.businesswire.com/news/home/20191219005171/en